HomeCompareBKFCF vs ABBV

BKFCF vs ABBV: Dividend Comparison 2026

BKFCF yields 5.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BKFCF wins by $12401.16M in total portfolio value
10 years
BKFCF
BKFCF
● Live price
5.65%
Share price
$0.88
Annual div
$0.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12401.26M
Annual income
$11,993,468,103.34
Full BKFCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BKFCF vs ABBV

📍 BKFCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBKFCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BKFCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BKFCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BKFCF
Annual income on $10K today (after 15% tax)
$480.24/yr
After 10yr DRIP, annual income (after tax)
$10,194,447,887.84/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BKFCF beats the other by $10,194,426,831.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BKFCF + ABBV for your $10,000?

BKFCF: 50%ABBV: 50%
100% ABBV50/50100% BKFCF
Portfolio after 10yr
$6200.68M
Annual income
$5,996,746,437.55/yr
Blended yield
96.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BKFCF
No analyst data
Altman Z
0.2
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BKFCF buys
0
ABBV buys
0
No recent congressional trades found for BKFCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBKFCFABBV
Forward yield5.65%3.06%
Annual dividend / share$0.05$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$12401.26M$102.3K
Annual income after 10y$11,993,468,103.34$24,771.77
Total dividends collected$12372.90M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BKFCF vs ABBV ($10,000, DRIP)

YearBKFCF PortfolioBKFCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,830$1,129.99$11,550$430.00+$280.00BKFCF
2$15,157$2,498.64$13,472$627.96+$1.7KBKFCF
3$22,201$5,983.71$15,906$926.08+$6.3KBKFCF
4$40,138$16,382.95$19,071$1,382.55+$21.1KBKFCF
5$98,311$55,362.85$23,302$2,095.81+$75.0KBKFCF
6$358,651$253,458.07$29,150$3,237.93+$329.5KBKFCF
7$2,112,068$1,728,311.77$37,536$5,121.41+$2.07MBKFCF
8$21,284,025$19,024,112.05$50,079$8,338.38+$21.23MBKFCF
9$381,114,860$358,340,952.85$69,753$14,065.80+$381.05MBKFCF
10$12,401,261,003$11,993,468,103.34$102,337$24,771.77+$12401.16MBKFCF

BKFCF vs ABBV: Complete Analysis 2026

BKFCFStock

Bank of Communications Co., Ltd. provides commercial banking products and services. The company operates through four business segments: Corporate Banking, Personal Banking, Treasury Businesses, and Other Businesses. It offers personal banking products and services, including savings deposit products, personal certificate of deposits, foreign currency deposit, and salary financing A products; mortgage and unsecured loans; bank cards; airport and personal wealth management advisor services; and physical precious metals, and structured deposits and wealth management products, as well as precious metal and commodity trading services. The company also provides corporate banking products and services comprising structured deposits and corporate certificate of deposits; syndicated loans and corporation overdraft services; wealth management services; investment banking and offshore banking services; corporate cash management and industrial chain financing services; structured deposits and wealth management products; and precious metal leasing, and precious metal and commodity trading services. In addition, it offers international banking services, such as corporate forex wealth management, document settlement, remittance and bill, and trade finance services; and interbank financing services. Further, the company provides financial leasing, trust investment, fund management, life insurance, securities dealing and brokerage, general insurance and reinsurance, debt-to-equity swaps, and financial products issuing and financial consulting services. As of December 31, 2021, It operated 248 branches in Mainland China; and 23 overseas branches and representative offices in 18 countries and regions with 69 overseas operating outlets. The company was founded in 1908 and is headquartered in Shanghai, the People's Republic of China.

Full BKFCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BKFCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BKFCF vs SCHDBKFCF vs JEPIBKFCF vs OBKFCF vs KOBKFCF vs MAINBKFCF vs JNJBKFCF vs MRKBKFCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.